» Articles » PMID: 10342684

A Markov Chain Model to Assess the Efficacy of Screening for Non-insulin Dependent Diabetes Mellitus (NIDDM)

Overview
Journal Int J Epidemiol
Specialty Public Health
Date 1999 May 26
PMID 10342684
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The high prevalence and severe consequences of non-insulin dependent diabetes mellitus (NIDDM) in Taiwan calls for urgent measures to detect this disease in the asymptomatic phase. However, the efficacy of early detection of NIDDM is highly dependent on its natural history from the disease-free state, through the asymptomatic to the symptomatic phase and death from NIDDM or other causes.

Methods: In order to project the above progression, a five-state illness-and-death Markov chain model was proposed to estimate these transition parameters using data from two rounds of a blood sugar screening programme for NIDDM in Puli, in central Taiwan.

Results: Results showed that the annual incidence for asymptomatic NIDDM was 10.67 per 1000 (95% CI: 8.26-13.79) and the average duration between the asymptomatic and symptomatic phases (the sojourn time) was 8 years (95%CI: 5.74-11.29). The 10-year survival rate for asymptomatic NIDDM (79.35%) was better than that for symptomatic NIDDM (69.45%). Prediction of deaths from NIDDM was performed to assess how the efficacy of screening for NIDDM varied by different screening frequencies (annual, biennial, 4-yearly and the control group). Results indicated there is no substantial difference in mortality reduction from NIDDM among the annual, biennial and 4-yearly screening regimens. However, a 4-yearly screening regimen significantly reduced deaths from NIDDM by 40% (95% CI: 26-51%).

Conclusions: A long sojourn time and the substantial reduction in mortality suggest that a 4-yearly screening regime for NIDDM would be most effective and feasible in Taiwan. The proposed five-state Markov chain model can be applied to other similar NIDDM screening projects.

Citing Articles

Dynamics of detailed components of metabolic syndrome associated with the risk of cardiovascular disease and death.

Lin T, Chien K, Chiu Y, Chuang P, Yen M, Chen H Sci Rep. 2021; 11(1):3677.

PMID: 33574366 PMC: 7878780. DOI: 10.1038/s41598-021-83118-y.


How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models' projections for England.

Bevan G, De Poli C, Keng M, Raine R BMJ Open. 2020; 10(3):e033483.

PMID: 32132137 PMC: 7059487. DOI: 10.1136/bmjopen-2019-033483.


Matrix methods in health demography: a new approach to the stochastic analysis of healthy longevity and DALYs.

Caswell H, Zarulli V Popul Health Metr. 2018; 16(1):8.

PMID: 29879982 PMC: 5992869. DOI: 10.1186/s12963-018-0165-5.


Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009.

Simmons R, Griffin S, Lauritzen T, Sandbaek A Diabetologia. 2017; 60(11):2192-2199.

PMID: 28831539 PMC: 6108415. DOI: 10.1007/s00125-017-4299-y.


Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults.

Simmons R, Griffin S, Witte D, Borch-Johnsen K, Lauritzen T, Sandbaek A Diabetologia. 2017; 60(11):2183-2191.

PMID: 28831535 PMC: 6086322. DOI: 10.1007/s00125-017-4323-2.